- Previous Close
47.02 - Open
47.20 - Bid --
- Ask --
- Day's Range
46.80 - 47.53 - 52 Week Range
13.72 - 48.32 - Volume
34,905 - Avg. Volume
669,439 - Market Cap (intraday)
2.787B - Beta (5Y Monthly) 2.16
- PE Ratio (TTM)
17.39 - EPS (TTM)
2.72 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
52.71
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
www.protagonist-inc.comRecent News: PTGX
View More
Performance Overview: PTGX
Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTGX
View MoreValuation Measures
Market Cap
2.77B
Enterprise Value
2.21B
Trailing P/E
17.28
Forward P/E
42.02
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.11
Price/Book (mrq)
5.11
Enterprise Value/Revenue
6.94
Enterprise Value/EBITDA
14.23
Financial Highlights
Profitability and Income Statement
Profit Margin
53.26%
Return on Assets (ttm)
20.35%
Return on Equity (ttm)
40.69%
Revenue (ttm)
319.12M
Net Income Avi to Common (ttm)
169.95M
Diluted EPS (ttm)
2.72
Balance Sheet and Cash Flow
Total Cash (mrq)
564M
Total Debt/Equity (mrq)
2.03%
Levered Free Cash Flow (ttm)
143.73M
Research Analysis: PTGX
View MoreCompany Insights: PTGX
PTGX does not have Company Insights
Research Reports: PTGX
View MoreRaising target price to $50.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $50.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $46.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $46.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $47.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $47.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $49.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $49.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target